In vitro microenvironments to study breast cancer bone colonisation

Advanced Drug Delivery Reviews

Volumn 79, Issue , 2014, Pages 135-144

  Taubenberger, Anna V ^a,b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Bone metastasis; Breast cancer; In vitro model; Tissue engineering; Tumour microenvironment

Indexed keywords

PATHOLOGY; PHYSIOLOGICAL MODELS; TISSUE ENGINEERING;

BONE METASTASIS; BREAST CANCER; BREAST CANCER CELLS; IN-VITRO MODELS; MICROENVIRONMENTS; MOLECULAR BASIS; PATHOPHYSIOLOGY; SYSTEMATIC STUDY;

DISEASES;

BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER MORTALITY; CANCER PATIENT; DRUG DETERMINATION; DRUG SCREENING; HUMAN; MORBIDITY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; BONE TUMOR; BREAST TUMOR; FEMALE; PATHOLOGY; PHYSIOLOGY; SECONDARY; TISSUE ENGINEERING;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MODELS, BIOLOGICAL; TISSUE ENGINEERING; TUMOR MICROENVIRONMENT;

EID: 84919664058     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.10.014     Document Type: Review

References (123)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64:9-29.
2. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989, 8:98-101.
3. Coleman R.E., Rubens R.D. The clinical course of bone metastases from breast cancer. Br. J. Cancer 1987, 55:61-66.
4. Wang C.Y., Wu G.Y., Shen M.J., Cui K.W., Shen Y. Comparison of distribution characteristics of metastatic bone lesions between breast and prostate carcinomas. Oncol. Lett. 2013, 5:391-397.
5. Coleman R.E., et al. Metastasis and bone loss: advancing treatment and prevention. Cancer Treat. Rev. 2010, 36:615-620.
6. Costa L., Major P.P. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat. Clin. Pract. Oncol. 2009, 6:163-174.
7. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2002, 2:584-593.
8. Nguyen D.X., Bos P.D., Massague J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 2009, 9:274-284.
9. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2:563-572.
10. Weiss L. Comments on hematogenous metastatic patterns in humans as revealed by autopsy. Clin. Exp. Metastasis 1992, 10:191-199.
11. Kang Y., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
12. Minn A.J., et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J. Clin. Invest. 2005, 115:44-55.
13. Kang Y., Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 2013, 23:573-581.
14. Casimiro S., Guise T.A., Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol. Cell. Endocrinol. 2009, 310:71-81.
15. Bussard K.M., Gay C.V., Mastro A.M. The bone microenvironment in metastasis; what is special about bone?. Cancer Metastasis Rev. 2008, 27:41-55.
16. Bussard K.M., Mastro A.M. Ex-vivo analysis of the bone microenvironment in bone metastatic breast cancer. J. Mammary Gland Biol. Neoplasia 2009, 14:387-395.
17. Kingsley L.A., Fournier P.G., Chirgwin J.M., Guise T.A. Molecular biology of bone metastasis. Mol. Cancer Ther. 2007, 6:2609-2617.
18. Guise T. Examining the metastatic niche: targeting the microenvironment. Semin. Oncol. 2010, 37(Suppl. 2):S2-S14.
19. Thomas R.J., Guise T.A., Yin J.J., Elliott J., Horwood N.J., Martin T.J., Gillespie M.T. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999, 140:4451-4458.
20. Guise T.A., et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Invest. 1996, 98:1544-1549.
21. Bendre M.S., Montague D.C., Peery T., Akel N.S., Gaddy D., Suva L.J. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 2003, 33:28-37.
22. Kozlow W., Guise T.A. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J. Mammary Gland Biol. Neoplasia 2005, 10:169-180.
23. Weilbaecher K.N., Guise T.A., McCauley L.K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 2011, 11:411-425.
24. Buijs J.T., van der Pluijm G. Osteotropic cancers: from primary tumor to bone. Cancer Lett. 2009, 273:177-193.
25. Kindt J.H., et al. In situ observation of fluoride-ion-induced hydroxyapatite-collagen detachment on bone fracture surfaces by atomic force microscopy. Nanotechnology 2007, 18:135102.
26. Hunter G.K., Hauschka P.V., Poole A.R., Rosenberg L.C., Goldberg H.A. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem. J. 1996, 317(Pt 1):59-64.
27. Hill A., McFarlane S., Johnston P.G., Waugh D.J. The emerging role of CD44 in regulating skeletal micrometastasis. Cancer Lett. 2006, 237:1-9.
28. Anborgh P.H., Mutrie J.C., Tuck A.B., Chambers A.F. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J. Cell. Mol. Med. 2010, 14:2037-2044.
29. Buijs J.T., Que I., Lowik C.W., Papapoulos S.E., van der Pluijm G. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Bone 2009, 44:380-386.
30. Yoneda T., Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem. Biophys. Res. Commun. 2005, 328:679-687.
31. Nakamura H., Hiraga T., Ninomiya T., Hosoya A., Fujisaki N., Yoneda T., Ozawa H. Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice. J. Bone Miner. Metab. 2008, 26:642-647.
32. Schneider J.G., Amend S.R., Weilbaecher K.N. Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone 2011, 48:54-65.
33. Esposito M., Kang Y. Targeting tumor-stromal interactions in bone metastasis. Pharmacol. Ther. 2014, 141:222-233.
34. Tuck A.B., Chambers A.F. The role of osteopontin in breast cancer: clinical and experimental studies. J. Mammary Gland Biol. Neoplasia 2001, 6:419-429.
35. Bauerle T., Peterschmitt J., Hilbig H., Kiessling F., Armbruster F.P., Berger M.R. Treatment of bone metastasis induced by MDA-MB-231 breast cancer cells with an antibody against bone sialoprotein. Int. J. Oncol. 2006, 28:573-583.
36. Elazar V., Adwan H., Bauerle T., Rohekar K., Golomb G., Berger M.R. Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis. Int. J. Cancer 2010, 126:1749-1760.
37. Robey P.G., et al. Structure and molecular regulation of bone matrix proteins. J. Bone Miner. Res. 1993, 8(Suppl. 2):S483-S487.
38. Hiraga T., et al. Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res. 2012, 72:4238-4249.
39. Guise T.A., Chirgwin J.M. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin. Orthop. Relat. Res. 2003, S32-S38.
40. Yin J.J., et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 1999, 103:197-206.
41. Guise T.A. Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev. 2009, 23:2117-2123.
42. Lu X., et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev. 2009, 23:1882-1894.
43. Campbell J.P., Merkel A.R., Masood-Campbell S.K., Elefteriou F., Sterling J.A. Models of bone metastasis. J. Vis. Exp. 2012, e4260.
44. Kuperwasser C., et al. A mouse model of human breast cancer metastasis to human bone. Cancer Res. 2005, 65:6130-6138.
45. Holzapfel B.M., et al. Humanised xenograft models of bone metastasis revisited: novel insights into species-specific mechanisms of cancer cell osteotropism. Cancer Metastasis Rev. 2013, 32:129-145.
46. Hutmacher D.W. Biomaterials offer cancer research the third dimension. Nat. Mater. 2010, 9:90-93.
47. Moreau J.E., Anderson K., Mauney J.R., Nguyen T., Kaplan D.L., Rosenblatt M. Tissue-engineered bone serves as a target for metastasis of human breast cancer in a mouse model. Cancer Res. 2007, 67:10304-10308.
48. Hutmacher D.W., Loessner D., Rizzi S., Kaplan D.L., Mooney D.J., Clements J.A. Can tissue engineering concepts advance tumor biology research?. Trends Biotechnol. 2010, 28:125-133.
49. Hutmacher D.W., et al. Translating tissue engineering technology platforms into cancer research. J. Cell. Mol. Med. 2009, 13:1417-1427.
50. van der Pluijm G., Vloedgraven H., Papapoulos S., Lowick C., Grzesik W., Kerr J., Robey P.G. Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components. Lab. Invest. 1997, 77:665-675.
51. van der Pluijm G., Vloedgraven H., van Beek E., van der Wee-Pals L., Lowik C., Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J. Clin. Invest. 1996, 98:698-705.
52. Lundstrom A., Holmbom J., Lindqvist C., Nordstrom T. The role of alpha2 beta1 and alpha3 beta1 integrin receptors in the initial anchoring of MDA-MB-231 human breast cancer cells to cortical bone matrix. Biochem. Biophys. Res. Commun. 1998, 250:735-740.
53. Nordstrom T., Knekt M., Nordstrom E., Lindqvist C. A microplate-based fluorometric assay for monitoring human cancer cell attachment to cortical bone. Anal. Biochem. 1999, 267:37-45.
54. Krawetz R., Wu Y.E., Rancourt D.E., Matyas J. Osteoblasts suppress high bone turnover caused by osteolytic breast cancer in-vitro. Exp. Cell Res. 2009, 315:2333-2342.
55. Curtin P., Youm H., Salih E. Three-dimensional cancer-bone metastasis model using ex-vivo co-cultures of live calvarial bones and cancer cells. Biomaterials 2012, 33:1065-1078.
56. Sung V., Stubbs J.T., Fisher L., Aaron A.D., Thompson E.W. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J. Cell. Physiol. 1998, 176:482-494.
57. Wong N.C., Mueller B.M., Barbas C.F., Ruminski P., Quaranta V., Lin E.C., Smith J.W. Alphav integrins mediate adhesion and migration of breast carcinoma cell lines. Clin. Exp. Metastasis 1998, 16:50-61.
58. Sloan E.K., Pouliot N., Stanley K.L., Chia J., Moseley J.M., Hards D.K., Anderson R.L. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 2006, 8:R20.
59. Engler A.J., Sen S., Sweeney H.L., Discher D.E. Matrix elasticity directs stem cell lineage specification. Cell 2006, 126:677-689.
60. Trappmann B., et al. Extracellular-matrix tethering regulates stem-cell fate. Nat. Mater. 2012, 11:642-649.
61. Heino J., Kapyla J. Cellular receptors of extracellular matrix molecules. Curr. Pharm. Des. 2009, 15:1309-1317.
62. van der Pluijm G., et al. Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am. J. Pathol. 2001, 159:971-982.
63. Yu H., Mouw J.K., Weaver V.M. Forcing form and function: biomechanical regulation of tumor evolution. Trends Cell Biol. 2011, 21:47-56.
64. Levental K.R., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
65. Ruppender N.S., Merkel A.R., Martin T.J., Mundy G.R., Sterling J.A., Guelcher S.A. Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells. PLoS ONE 2010, 5:e15451.
66. Yamada K.M., Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007, 130:601-610.
67. Serebriiskii I., Castello-Cros R., Lamb A., Golemis E.A., Cukierman E. Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. Matrix Biol. 2008, 27:573-585.
68. Kim J.B. Three-dimensional tissue culture models in cancer biology. Semin. Cancer Biol. 2005, 15:365-377.
69. Weigelt B., Bissell M.J. Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin. Cancer Biol. 2008, 18:311-321.
70. Vidi P.A., Bissell M.J., Lelievre S.A. Three-dimensional culture of human breast epithelial cells: the how and the why. Methods Mol. Biol. 2013, 945:193-219.
71. Kleinman H.K., Martin G.R. Matrigel: basement membrane matrix with biological activity. Semin. Cancer Biol. 2005, 15:378-386.
72. Ganapathy V., et al. Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol. Cancer 2010, 9:122.
73. Sasser A.K., et al. Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments. Cancer Lett. 2007, 254:255-264.
74. Beck J.N., Singh A., Rothenberg A.R., Elisseeff J.H., Ewald A.J. The independent roles of mechanical, structural and adhesion characteristics of 3D hydrogels on the regulation of cancer invasion and dissemination. Biomaterials 2013, 34:9486-9495.
75. Mitsiades C., Sourla A., Doillon C., Lembessis P., Koutsilieris M. Three-dimensional type I collagen co-culture systems for the study of cell-cell interactions and treatment response in bone metastases. J. Musculoskelet. Neuronal Interact. 2000, 1:153-155.
76. Bellahcene A., Merville M.P., Castronovo V. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res. 1994, 54:2823-2826.
77. Bellahcene A., Kroll M., Liebens F., Castronovo V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J. Bone Miner. Res. 1996, 11:665-670.
78. Cox R.F., Jenkinson A., Pohl K., O'Brien F.J., Morgan M.P. Osteomimicry of mammary adenocarcinoma cells in vitro; increased expression of bone matrix proteins and proliferation within a 3D collagen environment. PLoS ONE 2012, 7:e41679.
79. Endres M., et al. Osteogenic induction of human bone marrow-derived mesenchymal progenitor cells in novel synthetic polymer-hydrogel matrices. Tissue Eng. 2003, 9:689-702.
80. Pathi S.P., Kowalczewski C., Tadipatri R., Fischbach C. A novel 3-D mineralized tumor model to study breast cancer bone metastasis. PLoS ONE 2010, 5:e8849.
81. Pathi S.P., Lin D.D., Dorvee J.R., Estroff L.A., Fischbach C. Hydroxyapatite nanoparticle-containing scaffolds for the study of breast cancer bone metastasis. Biomaterials 2011, 32:5112-5122.
82. Brown T.D., Dalton P.D., Hutmacher D.W. Direct writing by way of melt electrospinning. Adv. Mater. 2011, 23:5651-5657.
83. Sieh S., Lubik A.A., Clements J.A., Nelson C.C., Hutmacher D.W. Interactions between human osteoblasts and prostate cancer cells in a novel 3D in vitro model. Organogenesis 2010, 6:181-188.
84. Yoneda T., Sasaki A., Dunstan C., Williams P.J., Bauss F., De Clerck Y.A., Mundy G.R. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J. Clin. Invest. 1997, 99:2509-2517.
85. Dhurjati R., Krishnan V., Shuman L.A., Mastro A.M., Vogler E.A. Metastatic breast cancer cells colonize and degrade three-dimensional osteoblastic tissue in vitro. Clin. Exp. Metastasis 2008, 25:741-752.
86. Lutter A.H., et al. A novel resorption assay for osteoclast functionality based on an osteoblast-derived native extracellular matrix. J. Cell. Biochem. 2010, 109:1025-1032.
87. Mercer R.R., Miyasaka C., Mastro A.M. Metastatic breast cancer cells suppress osteoblast adhesion and differentiation. Clin. Exp. Metastasis 2004, 21:427-435.
88. Mastro A.M., Vogler E.A. A three-dimensional osteogenic tissue model for the study of metastatic tumor cell interactions with bone. Cancer Res. 2009, 69:4097-4100.
89. Krishnan V., Shuman L.A., Sosnoski D.M., Dhurjati R., Vogler E.A., Mastro A.M. Dynamic interaction between breast cancer cells and osteoblastic tissue: comparison of two and three dimensional cultures. J. Cell. Physiol. 2011, 226:2150-2158.
90. Taubenberger A.V., Quent V.M., Thibaudeau L., Clements J.A., Hutmacher D.W. Delineating breast cancer cell interactions with engineered bone microenvironments. J. Bone Miner. Res. 2013, 28:1399-1411.
91. Castello-Cros R., Khan D.R., Simons J., Valianou M., Cukierman E. Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins. BMC Cancer 2009, 9:94.
92. Franceschi R.T., Iyer B.S., Cui Y. Effects of ascorbic acid on collagen matrix formation and osteoblast differentiation in murine MC3T3-E1 cells. J. Bone Miner. Res. 1994, 9:843-854.
93. Chung C.H., Golub E.E., Forbes E., Tokuoka T., Shapiro I.M. Mechanism of action of beta-glycerophosphate on bone cell mineralization. Calcif. Tissue Int. 1992, 51:305-311.
94. Langenbach F., Handschel J.R. Effects of dexamethasone, ascorbic acid and β-glycerophosphate on the osteogenic differentiation of stem cells in vitro. Stem. Cell Res. Ther. 2013, 4:117.
95. Sieh S., Taubenberger A.V., Lehman M.L., Clements J.A., Nelson C.C., Hutmacher D.W. Paracrine interactions between LNCaP prostate cancer cells and bioengineered bone in 3D in vitro culture reflect molecular changes during bone metastasis. Bone 2014, 63:121-131.
96. Dhurjati R., Liu X., Gay C.V., Mastro A.M., Vogler E.A. Extended-term culture of bone cells in a compartmentalized bioreactor. Tissue Eng. 2006, 12:3045-3054.
97. Kinder M., Chislock E., Bussard K.M., Shuman L., Mastro A.M. Metastatic breast cancer induces an osteoblast inflammatory response. Exp. Cell Res. 2008, 314:173-183.
98. Krishnan V., Vogler E.A., Sosnoski D.M., Mastro A.M. In vitro mimics of bone remodeling and the vicious cycle of cancer in bone. J. Cell. Physiol. 2014, 229:453-623.
99. Okazaki R., Conover C.A., Harris S.A., Spelsberg T.C., Riggs B.L. Normal human osteoblast-like cells consistently express genes for insulin-like growth factors I and II but transformed human osteoblast cell lines do not. J. Bone Miner. Res. 1995, 10:788-795.
100. Beacham D.A., Amatangelo M.D., Cukierman E. Preparation of extracellular matrices produced by cultured and primary fibroblasts. Curr. Protoc. Cell Biol. 2007, Chapter 10. (Unit 10 9).
101. Reichert J.C., Quent V.M., Burke L.J., Stansfield S.H., Clements J.A., Hutmacher D.W. Mineralized human primary osteoblast matrices as a model system to analyse interactions of prostate cancer cells with the bone microenvironment. Biomaterials 2010, 31:7928-7936.
102. Dumont N., et al. Breast fibroblasts modulate early dissemination, tumorigenesis, and metastasis through alteration of extracellular matrix characteristics. Neoplasia 2013, 15:249-262.
103. Goetz J.G., et al. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 2011, 146:148-163.
104. Peng Y., et al. Human fibroblast matrices bio-assembled under macromolecular crowding support stable propagation of human embryonic stem cells. J. Tissue Eng. Regen. Med. 2012, 6:e74-e86.
105. Lareu R.R., et al. Collagen matrix deposition is dramatically enhanced in vitro when crowded with charged macromolecules: the biological relevance of the excluded volume effect. FEBS Lett. 2007, 581:2709-2714.
106. Chandler E.M., et al. Implanted adipose progenitor cells as physicochemical regulators of breast cancer. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:9786-9791.
107. Leight J.L., Wozniak M.A., Chen S., Lynch M.L., Chen C.S. Matrix rigidity regulates a switch between TGF-beta1-induced apoptosis and epithelial-mesenchymal transition. Mol. Biol. Cell 2012, 23:781-791.
108. Eliasson P., Jonsson J.I. The hematopoietic stem cell niche: low in oxygen but a nice place to be. J. Cell. Physiol. 2010, 222:17-22.
109. Spencer J.A., et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature 2014, 508:269-273.
110. Wu D., Yotnda P. Induction and testing of hypoxia in cell culture. J. Vis. Exp. 2011, 12.
111. Wenger A., Stahl A., Weber H., Finkenzeller G., Augustin H.G., Stark G.B., Kneser U. Modulation of in vitro angiogenesis in a three-dimensional spheroidal coculture model for bone tissue engineering. Tissue Eng. 2004, 10:1536-1547.
112. Cenni E., Perut F., Baldini N. In vitro models for the evaluation of angiogenic potential in bone engineering. Acta Pharmacol. Sin. 2011, 32:21-30.
113. Szot C.S., Buchanan C.F., Freeman J.W., Rylander M.N. In vitro angiogenesis induced by tumor-endothelial cell co-culture in bilayered, collagen I hydrogel bioengineered tumors. Tissue Eng. C Methods 2013, 19:864-874.
114. Correa de Sampaio P., Auslaender D., Krubasik D., Failla A.V., Skepper J.N., Murphy G., English W.R. A heterogeneous in vitro three dimensional model of tumour-stroma interactions regulating sprouting angiogenesis. PLoS ONE 2012, 7:e30753.
115. Chwalek K., Bray L.J., Werner C. Tissue-engineered 3D tumor angiogenesis models: potential technologies for anti-cancer drug discovery. Adv. Drug Deliv. Rev. 2014, (Epub ahead of print, in this issue).
116. Safuan S., Storr S.J., Patel P.M., Martin S.G. A comparative study of adhesion of melanoma and breast cancer cells to blood and lymphatic endothelium. Lymphat. Res. Biol. 2012, 10:173-181.
117. Zen K., et al. CD44v4 is a major E-selectin ligand that mediates breast cancer cell transendothelial migration. PLoS ONE 2008, 3:e1826.
118. Polacheck W.J., Li R., Uzel S.G., Kamm R.D. Microfluidic platforms for mechanobiology. Lab Chip 2013, 13:2252-2267.
119. Bersini S., Jeon J.S., Moretti M., Kamm R.D. In vitro models of the metastatic cascade: from local invasion to extravasation. Drug Discov. Today 2014, 19:735-742.
120. Zervantonakis I.K., Hughes-Alford S.K., Charest J.L., Condeelis J.S., Gertler F.B., Kamm R.D. Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:13515-13520.
121. Jeon J.S., Zervantonakis I.K., Chung S., Kamm R.D., Charest J.L. In vitro model of tumor cell extravasation. PLoS ONE 2013, 8:e56910.
122. Chen M.B., Whisler J.A., Jeon J.S., Kamm R.D. Mechanisms of tumor cell extravasation in an in vitro microvascular network platform. Integr. Biol. (Camb.) 2013, 5:1262-1271.
123. Miles F.L., Pruitt F.L., van Golen K.L., Cooper C.R. Stepping out of the flow: capillary extravasation in cancer metastasis. Clin. Exp. Metastasis 2008, 25:305-324.